The Mn porphyrins of k(cat)(O(2)(.-)) as high as that of a superoxide dismutase enzyme and of optimized lipophilicity have already been synthesized. Their exceptional in vivo potency is at least in part due to their ability to mimic the site and location of mitochondrial superoxide dismutase, MnSOD. MnTnHex-2-PyP(5+) is the most studied among lipophilic Mn porphyrins. It is of remarkable efficacy in animal models of oxidative stress injuries and particularly in central nervous system diseases. However, when used at high single and multiple doses it becomes toxic. The toxicity of MnTnHex-2-PyP(5+) has been in part attributed to its micellar properties, i.e., the presence of polar cationic nitrogens and hydrophobic alkyl chains. The replacement of a CH(2) group by an oxygen atom in each of the four alkyl chains was meant to disrupt the porphyrin micellar character. When such modification occurs at the end of long alkyl chains, the oxygens become heavily solvated, which leads to a significant drop in the lipophilicity of porphyrin. However, when the oxygen atoms are buried deeper within the long heptyl chains, their excessive solvation is precluded and the lipophilicity preserved. The presence of oxygens and the high lipophilicity bestow the exceptional chemical and physical properties to Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin, MnTnBuOE-2-PyP(5+). The high SOD-like activity is preserved and even enhanced: log k(cat)(O(2)(.-))=7.83 vs 7.48 and 7.65 for MnTnHex-2-PyP(5+) and MnTnHep-2-PyP(5+), respectively. MnTnBuOE-2-PyP(5+) was tested in an O(2)(.-) -specific in vivo assay, aerobic growth of SOD-deficient yeast, Saccharomyces cerevisiae, where it was fully protective in the range of 5-30 μM. MnTnHep-2-PyP(5+) was already toxic at 5 μM, and MnTnHex-2-PyP(5+) became toxic at 30 μM. In a mouse toxicity study, MnTnBuOE-2-PyP(5+) was several-fold less toxic than either MnTnHex-2-PyP(5+) or MnTnHep-2-PyP(5+).
The Mn porphyrins of k(cat)(O(2)(.-)) as high as that of a n class="Chemical">superoxide dismutase enzyme and of optimized lipophilicity have already been synthesized. Their exceptional in vivo potency is at least in part due to their ability to mimic the site and location of mitochondrial superoxide dismutase, MnSOD. MnTnHex-2-PyP(5+) is the most studied among lipophilic Mn porphyrins. It is of remarkable efficacy in animal models of oxidative stress injuries and particularly in central nervous system diseases. However, when used at high single and multiple doses it becomes toxic. The toxicity of MnTnHex-2-PyP(5+) has been in part attributed to its micellar properties, i.e., the presence of polar cationic nitrogens and hydrophobic alkyl chains. The replacement of a CH(2) group by an oxygen atom in each of the four alkyl chains was meant to disrupt the porphyrinmicellar character. When such modification occurs at the end of long alkyl chains, the oxygens become heavily solvated, which leads to a significant drop in the lipophilicity of porphyrin. However, when the oxygen atoms are buried deeper within the long heptyl chains, their excessive solvation is precluded and the lipophilicity preserved. The presence of oxygens and the high lipophilicity bestow the exceptional chemical and physical properties to Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin, MnTnBuOE-2-PyP(5+). The high SOD-like activity is preserved and even enhanced: log k(cat)(O(2)(.-))=7.83 vs 7.48 and 7.65 for MnTnHex-2-PyP(5+) and MnTnHep-2-PyP(5+), respectively. MnTnBuOE-2-PyP(5+) was tested in an O(2)(.-) -specific in vivo assay, aerobic growth of SOD-deficient yeast, Saccharomyces cerevisiae, where it was fully protective in the range of 5-30 μM. MnTnHep-2-PyP(5+) was already toxic at 5 μM, and MnTnHex-2-PyP(5+) became toxic at 30 μM. In a mousetoxicity study, MnTnBuOE-2-PyP(5+) was several-fold less toxic than either MnTnHex-2-PyP(5+) or MnTnHep-2-PyP(5+).
Authors: Ines Batinic-Haberle; Zrinka Rajic; Artak Tovmasyan; Julio S Reboucas; Xiaodong Ye; Kam W Leong; Mark W Dewhirst; Zeljko Vujaskovic; Ludmil Benov; Ivan Spasojevic Journal: Free Radic Biol Med Date: 2011-05-06 Impact factor: 7.376
Authors: I Spasojević; I Batinić-Haberle; R D Stevens; P Hambright; A N Thorpe; J Grodkowski; P Neta; I Fridovich Journal: Inorg Chem Date: 2001-02-12 Impact factor: 5.165
Authors: Xiaodong Ye; Diane Fels; Artak Tovmasyan; Katherine M Aird; Casey Dedeugd; Jennifer L Allensworth; Ivan Kos; Won Park; Ivan Spasojevic; Gayathri R Devi; Mark W Dewhirst; Kam W Leong; Ines Batinic-Haberle Journal: Free Radic Res Date: 2011-09-27
Authors: Artak G Tovmasyan; Zrinka Rajic; Ivan Spasojevic; Julio S Reboucas; Xin Chen; Daniela Salvemini; Huaxin Sheng; David S Warner; Ludmil Benov; Ines Batinic-Haberle Journal: Dalton Trans Date: 2011-03-08 Impact factor: 4.390
Authors: Ines Batinić-Haberle; Ivan Spasojević; Robert D Stevens; Peter Hambright; Pedatsur Neta; Ayako Okado-Matsumoto; Irwin Fridovich Journal: Dalton Trans Date: 2004-05-05 Impact factor: 4.390
Authors: Huaxin Sheng; Jan J Enghild; Russell Bowler; Manisha Patel; Ines Batinić-Haberle; Carla L Calvi; Brian J Day; Robert D Pearlstein; James D Crapo; David S Warner Journal: Free Radic Biol Med Date: 2002-10-01 Impact factor: 7.376
Authors: Jim Zhong; Narasimhan Rajaram; David M Brizel; Amy E Frees; Nirmala Ramanujam; Ines Batinic-Haberle; Mark W Dewhirst Journal: Radiother Oncol Date: 2013-03-28 Impact factor: 6.280
Authors: Y Zhao; S Miriyala; L Miao; M Mitov; D Schnell; S K Dhar; J Cai; J B Klein; R Sultana; D A Butterfield; M Vore; I Batinic-Haberle; S Bondada; D K St Clair Journal: Free Radic Biol Med Date: 2014-03-12 Impact factor: 7.376
Authors: Douglas H Weitzel; Artak Tovmasyan; Kathleen A Ashcraft; Zrinka Rajic; Tin Weitner; Chunlei Liu; Wei Li; Anne F Buckley; Mark R Prasad; Kenneth H Young; Ramona M Rodriguiz; William C Wetsel; Katherine B Peters; Ivan Spasojevic; James E Herndon; Ines Batinic-Haberle; Mark W Dewhirst Journal: Mol Cancer Ther Date: 2014-10-15 Impact factor: 6.261
Authors: Samuel R Birer; Chen-Ting Lee; Kingshuk Roy Choudhury; Kenneth H Young; Ivan Spasojevic; Ines Batinic-Haberle; James D Crapo; Mark W Dewhirst; Kathleen A Ashcraft Journal: Radiat Res Date: 2017-05-18 Impact factor: 2.841
Authors: Artak Tovmasyan; Jacqueline C Bueno-Janice; Melba C Jaramillo; Romulo S Sampaio; Julio S Reboucas; Natalia Kyui; Ludmil Benov; Brian Deng; Ting-Ting Huang; Margaret E Tome; Ivan Spasojevic; Ines Batinic-Haberle Journal: Antioxid Redox Signal Date: 2018-03-27 Impact factor: 8.401
Authors: Tin Weitner; Ivan Kos; Huaxin Sheng; Artak Tovmasyan; Julio S Reboucas; Ping Fan; David S Warner; Zeljko Vujaskovic; Ines Batinic-Haberle; Ivan Spasojevic Journal: Free Radic Biol Med Date: 2013-01-15 Impact factor: 7.376